Accelerator
CARB-X
ILSE is proud to contribute to combating the global AMR threat by serving as the only US-based Global Accelerator Network Partner to CARB-X.
Antimicrobial Resistance
Is a top public health threat responsible for the deaths of millions around the world, requiring a globally coordinated effort to counter it.
Global Accelerator Network
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is one of the largest and most promising global non-profit partnerships addressing AMR by supporting the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria.
CARB-X supports the world’s most scientifically diverse, early development pipeline of antibiotics, vaccines, and diagnostics to prevent, diagnose and treat bacterial infections.
We increase the chances of success
We provide our expertise in antibacterial drug development, R&D program management, business strategy and areas essential to supporting CARB-X’s portfolio of early development research projects to increase their chances of success.
To explore if your program is the right fit for CARB-X please visit the website here https://carb-x.org or contact us